Top

Published in:

01-10-2009 | Original Research Article

Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy

Authors: Mrs F. F. Tessa Ververs, Heronimus A. M. Voorbij, Petra Zwarts, Svetlana V. Belitser, Toine C. G. Egberts, Gerard H. A. Visser, Alfred F. A. M. Schobben

Published in: Clinical Pharmacokinetics | Issue 10/2009

Abstract

Background and Objective

Increasing numbers of women in childbearing years are treated with antidepressants. Concerns regarding fetal exposure to medication has led to large studies on drug effects on birth outcome and on the risk of congenital anomalies. The risk of adverse effects due to paroxetine use during pregnancy has been associated with the extent of exposure. Nevertheless, few studies have covered dosing aspects in order to minimize fetal antidepressant exposure while limiting the risk of treatment failure. Essential pharmacokinetic data in pregnancy are lacking, even regarding paroxetine, one of the most commonly used antidepressants. We examined the changes of maternal paroxetine concentrations during pregnancy in relation to cytochrome P450 (CYP) 2D6 genotype.

Method

An observational cohort study was conducted in 74 pregnant women aged from 25 to 45 years treated with paroxetine during pregnancy. Blood samples and information on dosing, weight, smoking and mood were provided at 16–20, 27–31 and 36–40 weeks of pregnancy. Samples were analysed for paroxetine plasma concentrations and CYP2D6 genotype.

Results

Women who were genotyped as extensive metabolizers (EMs) or ultra-rapid metabolizers (UMs) for CYP2D6 (EM n = 43; UM n=1) showed steadily decreasing plasma paroxetine concentrations during the course of pregnancy, with a decrease of 0.3 µg/L (95% CI −0.58, −0.07) for each week of pregnancy. In contrast, plasma paroxetine concentrations of intermediate metabolizers (IMs [n = 25]) and poor metabolizers (PMs [n = 5]) increased during pregnancy, resulting in an increase of 0.82 µg/L (95% CI 0.42, 1.22) for each week of pregnancy. Weight gain, maternal age or smoking did not influence plasma drug concentrations. Decreasing plasma concentrations in EMs are in accordance with induced CYP2D6 activity during pregnancy. Accumulation of paroxetine in women with impaired CYP2D6 metabolism may be explained by competition with an endogenous substrate. In EMs/UMs the depressive symptoms increased significantly during the course of pregnancy, while in the IM/PM group these did not change.

Conclusions

Differences in CYP2D6 genotype may have divergent effects on maternal plasma paroxetine concentrations during pregnancy, with therapeutic consequences. Accumulation of paroxetine in a considerable group of pregnant women will lead to unintended increased exposure of paroxetine to the unborn child. Knowledge about a patient’s CYP2D6 genotype is indispensable when prescribing paroxetine in pregnancy [trialregister.nl Identifier ISRCTN25383361].

Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198(2): 194.el–5CrossRef

Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25(1): 59–73PubMedCrossRef

Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65(4): 600–6PubMedCrossRef

Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62(10): 863–70PubMedCrossRef

Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295(5): 499–507PubMedCrossRef

Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008; 69(4): 652–8PubMedCrossRef

Hostetter A, Stowe ZN, Strader Jr JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11(2): 51–7PubMedCrossRef

Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006; 61(2): 155–63PubMedCrossRef

Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73(4): 330–7PubMedCrossRef

10.

Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60(2): 183–90PubMedCrossRef

11.

Haffen E, Vandel P, Broly F, et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32: 232–4PubMedCrossRef

12.

Sindrup SH, Brøsen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11–7PubMedCrossRef

13.

Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27: 763–6PubMed

14.

DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247–66PubMedCrossRef

15.

Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33: 262–70PubMedCrossRef

16.

Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–92PubMedCrossRef

17.

Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol 1999; 48: 416–23PubMedCrossRef

18.

Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Drug Monit 2002; 22: 143–54CrossRef

19.

Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3(2): 229–43PubMedCrossRef

20.

Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60(5): 512–21PubMedCrossRef

21.

Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60(5): 329–36PubMedCrossRef

22.

Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51(3): 288–95PubMedCrossRef

23.

Spigset O, Granberg K, Hagg S, et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52(2): 129–33PubMedCrossRef

24.

Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57(10): 717–22PubMedCrossRef

25.

Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44(10): 989–1008PubMedCrossRef

26.

Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293(19): 2372–83PubMedCrossRef

27.

Cox JL, Chapman G, Murray D, et al. Validation of the Edinburgh Postnatal Depression Scale (EPDS) in non-postnatal women. J Affect Disord 1996; 39(3): 185–9PubMedCrossRef

28.

Blakesley JD, Howse CG, Spencer-Peet J, et al. An improved method for measurement of common tricyclic antidepressant drugs and their metabolites using normal phase HPLC. Ann Clin Biochem 1986; 23(Pt 5): 552–8PubMed

29.

Sauvage FL, Gaulier JM, Lachatre G, et al. A fully automated turbulentflow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit 2006; 28(1): 123–30PubMedCrossRef

30.

Schenk PW, van Fessem MA, Verploegh-Van Rij S, et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13(6): 597–605PubMedCrossRef

31.

Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005; 192(2): 633–9PubMedCrossRef

32.

Wadelius MM, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997 Oct; 624: 400–7CrossRef

33.

Dickmann LJ, Tay S, Senn TD, et al. Changes in maternal liver CYP2C and CYP2D expression and activity during rat pregnancy. Biochem Pharmacol 2008; 75(8): 1677–87PubMedCrossRef

34.

Tasker TC, Kaye CM, Zussman BD, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350: 152–5PubMedCrossRef

35.

Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323(7307): 257–60PubMedCrossRef

36.

Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80(1): 18–27PubMedCrossRef

37.

Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192(5): 338–43PubMedCrossRef

38.

Noorlander CW, Ververs FF, Nikkels PG, et al. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008; 3(7): e2782PubMedCrossRef

39.

DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006; 20 (4 Suppl.): 54–9PubMedCrossRef

Title: Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy
Authors: Mrs F. F. Tessa Ververs
Heronimus A. M. Voorbij
Petra Zwarts
Svetlana V. Belitser
Toine C. G. Egberts
Gerard H. A. Visser
Alfred F. A. M. Schobben
Publication date: 01-10-2009
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 10/2009
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/11318050-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy

Abstract

Background and Objective

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Objective

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2009

Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration

Pharmacology of Morphine in Obese Patients

The Authors’ Reply

Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation

A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling

Bioequivalence Criteria for Transdermal Fentanyl Generics